OSTX
OS Therapies Incorporated1.6200
-0.0500-2.99%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
57.05MP/E (TTM)
-Basic EPS (TTM)
-0.81Dividend Yield
0%Recent Filings
8-K
Prospectus for 10.5M share resale
OS Therapies filed a prospectus supplement on March 31, 2026, enabling resale of up to 10,529,417 common shares by selling stockholders under its effective S-3 registration. The filing includes a legal opinion from Olshan Frome Wolosky LLP affirming the shares' legality. No new capital raise for the company.
10-K
FY2025 results
OS Therapies posted FY2025 net loss of $28.8M on $28.7M operating expenses, up from $8.9M loss in FY2024, as R&D surged to $16.4M from $2.8M on OST-HER2 regulatory prep while G&A hit $12.3M from $4.0M on financing costs. Q4 accelerated BLA module submission post non-clinical/CMC filing, building on Phase IIb's 75% two-year survival (27/36 evaluable patients) vs 40% historical control. Warrant exercises drove $9.4M cash inflow yet ended year with $0.3M cash amid $11.6M payables. OST-HER2 Phase IIb met primary endpoint; BLA clinical module and EU/UK MAAs eyed Q2 2026. Auditors flag going concern doubt from losses and capital needs.
8-K
OS Therapies raises $2M
OS Therapies closed a $2M private placement on March 4, 2026, issuing $2.2M principal 10% OID convertible notes maturing March 4, 2027, plus warrants for 1,666,667 shares at $1.40. Funds fuel clinical trials and R&D. Notes convert at 90% VWAP or Qualified Offering price; 19.99% cap binds without shareholder vote. Dilution looms large.
8-K
Warrant offer extended
OS Therapies extended its warrant inducement offer to March 2, 2026, after launching it January 10 for less than 10 holders of existing warrants covering 5,382,148 shares. Holders exercise at $1.40 per share—or $1.399 for pre-funding—in exchange for new warrants at $1.40. Extension buys time. No cash proceeds disclosed yet.
8-K
Raises $7.5M via warrant inducement
OS Therapies inked inducement deals on January 10, 2026, with nine holders to exercise 5.4 million existing warrants at $1.40/share, netting ~$7.5M gross proceeds after fees. New warrants match the count, exercisable at $1.40 for five years. Funds runway into 2027 for OST-HER2 regulatory pushes and OS Animal Health spinoff prep. All offered investors joined.
ATOS
Atossa Therapeutics, Inc.
0.72+0.01
FATE
Fate Therapeutics, Inc.
1.09-0.03
GRCE
Grace Therapeutics, Inc.
3.34+0.10
GTBP
GT Biopharma, Inc.
0.72+0.09
LSTA
Lisata Therapeutics, Inc.
2.05+0.01
MRKR
Marker Therapeutics, Inc.
1.27-0.12
ORGS
Orgenesis, Inc.
0.15-0.01
ORKA
Oruka Therapeutics, Inc.
28.94-1.16
OSRH
OSR Holdings, Inc.
0.55-0.02
OTLC
Oncotelic Therapeutics, Inc.
0.09+0.00